VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "hold" rating restated by research analysts at Benchmark in a research note issued to investors on Friday,Benzinga reports.
Separately, StockNews.com initiated coverage on VolitionRx in a research note on Wednesday. They issued a "sell" rating on the stock.
Check Out Our Latest Report on VolitionRx
VolitionRx Price Performance
Shares of VolitionRx stock traded down $0.02 on Friday, reaching $0.79. 57,920 shares of the company were exchanged, compared to its average volume of 160,267. The stock's 50 day moving average price is $0.69 and its 200-day moving average price is $0.68. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23. The company has a market cap of $73.57 million, a P/E ratio of -2.21 and a beta of 1.10.
Institutional Trading of VolitionRx
A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC increased its position in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company's stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is owned by institutional investors and hedge funds.
VolitionRx Company Profile
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Stories
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
